Yi Wang

Yi Wang is a highly experienced director specializing in mRNA technology and therapeutics, with a current role at Everest Medicines since November 2021, where responsibilities include leading the mRNA rabies vaccine project and developing mRNA technology and lipid nanoparticle platforms. Previous positions include R&D Director at NANOPEPTIDE (QINGDAO) BIOTECHNOLOGY LTD, focusing on siRNA drug development, and Chief Scientist at ExonanoRNA, leading RNA oligo and nanoparticle projects for cancer therapeutics. Yi Wang's academic background includes a Doctor of Philosophy (PhD) from Louisiana State University and research experience at esteemed institutions such as the University of Florida College of Medicine and the Masonic Cancer Center, University of Minnesota, emphasizing cancer biomarker identification and drug development.